Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06224660 · ClinicalTrials.gov registry record · Phase 1
Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
A Phase 1 study of DMD-Associated Dilated Cardiomyopathy, sponsored by Sardocor.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06224660 is a Phase 1 study of DMD-Associated Dilated Cardiomyopathy that is actively recruiting participants, run by Sardocor. The registered enrollment target is 12 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT06224660, a Phase 1 study of DMD-Associated Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Sardocor.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is testing whether an experimental drug, called SRD-001, is safe and helps the weakened heart of patients with Duchenne muscular dystrophy (DMD) regain its ability to effectively pump blood to the rest of the body. SRD-001 is a form of gene therapy. The goal of SRD-001 gene therapy is to provide the heart muscle cells with extra copies of the SERCA2a gene so that they can produce more SERCA2a protein to help the heart muscle cells squeeze/contract better. Researchers will compare SRD-001 treated participants with no-treatment participants; all participants will continue to take their current heart medications. All participants will be followed very closely for 2 years and undergo cardiac magnetic resonance imaging of their heart at baseline, year 1 and year 2 along with assessment of upper limb function and lung function. After the 2 years of close follow-up, all participants will roll over into long-term follow-up where they will be called biannually for information on their current medical status.
Conditions Studied
Interventions
- GENETIC SRD-001
Study Locations (3)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Kansas
- The University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2030-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06224660
The ClinicalTrials.gov registry entry for NCT06224660 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sardocor, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with DMD-Associated Dilated Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which SRD-001 is the first listed.
NCT06224660 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Kansas.
Frequently Asked Questions
What is clinical trial NCT06224660 about?
NCT06224660 is a clinical study titled "Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy". This research study is testing whether an experimental drug, called SRD-001, is safe and helps the weakened heart of patients with Duchenne muscular dystrophy (DMD) regain its ability to effectively pump blood to the rest of the body. SRD-001 is a form of gene therapy. The goal of SRD-001 gene thera...
What is the current status of trial NCT06224660?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-10-02. Estimated completion is 2030-10.
What conditions does trial NCT06224660 study?
This clinical trial studies the following conditions: DMD-Associated Dilated Cardiomyopathy.
What interventions are being tested in trial NCT06224660?
The interventions under investigation include: SRD-001 (GENETIC).
Who is sponsoring clinical trial NCT06224660?
This trial is sponsored by Sardocor, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06224660 being conducted?
This trial has 3 study locations across Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.